We don't know if it is eteplirsin but its a case of what else could it be! The announcement of a successful outcome to studies conducted by Fletcher and Wilton from Murdoch University that a CPP can improve the delivery of an antisense oligonucleotide drug is out of the blue.
The clinical trial of Eteplirsin has provided hope for DMD patients - it is the 'first drug known to treat the disease'. Within this context, an improvement in the efficiency of delivery inside cells is extremely promising. The next step - outlined in the announcement - is whether improved delivery leads to better outcomes. It is worth noting that the collaboration between Phylogica and the team from Murdoch University was initiated in February 2016 and the outcome of additional studies is expected in H2 2016. I didn't realise medical research could move so quickly.
There appears to be a growing momentum as Phylogica's platform and the science of intracellular delivery becomes more mature.
PYC Price at posting:
1.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)